Variations in CARD16, a gene involved in inflammation and apoptosis, could influence the pharmacodynamics of ribavirin, an antiviral drug used against hepatitis C, by modifying immune system responses. This interaction does not affect the metabolism or distribution of ribavirin but potentially its effectiveness through immune modulation.